Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 4, 2026International Journal of NanomedicineOpen Access

Smart Colloidal Systems as Drug Delivery and Therapeutic Modulation Platforms for Renal Cell Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLiming SunXZXinming ZhaoXLXiaoting Li

Discussion

Loading...

Member takes

Overview

Narrative review highlights therapeutic advances of smart colloidal drug delivery systems in renal cell carcinoma, suggesting engineered nanocarriers can overcome current treatment resistance.

Key Points

  • To review the development, therapeutic mechanisms, and translational feasibility of smart colloidal delivery systems designed to overcome treatment resistance and systemic toxicity in advanced renal cell carcinoma.
  • Synthesized preclinical and clinical literature evaluating engineered colloidal carriers across diverse modalities for renal cell carcinoma therapy.
  • Assessed carrier platforms delivering targeted inhibitors, immune modulators, nucleic acids, ferroptosis agents, and stimulus-responsive triggers.
  • Analyzed clinical translation barriers, including carrier biodistribution, manufacturing scalability, renal clearance, and organ safety profiles.
  • Smart colloidal platforms qualitatively enhanced drug stability, localized tumor accumulation, and stimulus-responsive intracellular release across multiple treatment classes.
  • Multimodal formulations successfully combined immunogenic cell death, ferroptosis induction, and checkpoint modulation in preclinical cancer models.
  • The majority of smart colloidal designs remain limited to preclinical evaluation due to ongoing challenges in manufacturing feasibility, systemic toxicity, and immune compatibility.

Cite This Study

Sun et al. (2026) studied this question.

synapsesocial.com/papers/6a9a85d25d9e33f25c631220https://doi.org/10.2147/ijn.s590442
View Full Paper
Ask AI
Bookmark
Share